Patient-centred purpose
Keeping the needs of patients and healthcare systems at the centre of responsible development.
Zimbabwean Pharmaceutical Manufacturing
Advancing access to essential medicines through modern pharmaceutical manufacturing.
Biogenix is being developed as a Zimbabwe-based pharmaceutical manufacturing platform, beginning with essential IV fluids and progressing into selected generic injectable medicines. Our strategy starts in Zimbabwe, focuses on Southern Africa’s SADC markets and looks toward wider Africa over time.
Products and commercial availability remain subject to manufacturing readiness and applicable regulatory approvals.
Who We Are
Building pharmaceutical manufacturing capability around access, quality and reliability.
Biogenix is a pharmaceutical manufacturing company being developed in Zimbabwe with a clear purpose: to help strengthen access to essential medicines through reliable local manufacturing capability, with Zimbabwe as the launch base and SADC as the principal regional market.
Our initial strategic focus is sterile large-volume parenteral IV fluids, supported by a long-term plan to develop a carefully selected portfolio of generic injectable medicines.
Quality by design
Building quality thinking into the intended product and process lifecycle from the outset.
Reliable supply ambition
Working toward dependable local capability for medicines that healthcare institutions rely on.
Our Manufacturing Focus
A focused path from essential IV fluids to selected injectable medicines.
Initial strategic focus
Sterile IV Fluids
Biogenix’s proposed first manufacturing platform is focused on large-volume parenteral IV fluids used across hospitals and other clinical environments.
Future portfolio
Generic Injectable Medicines
Over time, Biogenix intends to expand into selected generic injectable medicines based on clinical need, technical feasibility, market requirements and regulatory approval.
Planned Portfolio
An initial focus on essential intravenous fluids.
The proposed portfolio is centred on commonly required IV-fluid categories. Final products, pack sizes, specifications and launch timing will depend on technical development, market assessment and regulatory approval.
Initial IV-fluid portfolio conceptDevelopment-stage artwork
Development-stage visual: Packaging, strengths, presentations, label wording and product availability remain subject to technical and regulatory review. This artwork does not represent registered or commercially available products.
- Status: Planned
0.9% Sodium Chloride Injection
Planned sterile IV fluid
- Status: Planned
Ringer's Lactate Injection
Planned sterile IV fluid
- Status: Planned
5% Dextrose Injection
Planned sterile IV fluid
- Status: Planned
10% Dextrose Injection
Planned sterile IV fluid
- Status: Planned
Hypertonic Saline
Planned sterile IV fluid
Quality and Patient Safety
Quality is designed into every stage, not inspected in at the end.
Biogenix’s quality approach is being developed to extend from the selection of materials through manufacturing, testing, release, distribution and post-market monitoring.
These quality principles guide the planned model and the systems being developed for regulatory readiness.
- 01Quality by design
- 02Patient safety first
- 03Controlled manufacturing
- 04Traceability
- 05Regulatory responsibility
- 06Continuous improvement
Manufacturing and Technology
A planned sterile manufacturing platform supported by controlled processes.
Biogenix is evaluating appropriate modern manufacturing technologies for its proposed IV-fluid platform, including automated sterile processes and Blow-Fill-Seal technology.
Technology selection, process design and facility capabilities remain under evaluation.
Planned manufacturing model
From controlled inputs to responsible release
Proposed process sequence
- 01Raw materials and pharmaceutical water
- 02Controlled compounding
- 03Container formation and filling
- 04Inspection and in-process testing
- 05Packaging and batch release
- 06Controlled storage and distribution
Supporting capability themes
Systems intended to work as one controlled environment.
The proposed platform considers the connected infrastructure, monitoring, documentation and testing needed to support responsible sterile manufacturing.
- Pharmaceutical water systems
- Cleanrooms and HVAC
- Environmental monitoring
- Laboratory testing
- Batch documentation
- Material-to-product traceability
Why It Matters
Zimbabwean manufacturing with a regional purpose
Biogenix is being developed to manufacture essential medicines in Zimbabwe while progressively building the regulatory, distribution and commercial capabilities required to serve selected Southern African Development Community (SADC) markets.
- 01
Essential-medicine manufacturing
A planned manufacturing base closer to domestic and regional healthcare needs.
- 02
Shorter regional supply chains
Manufacturing in Zimbabwe could reduce exposure to distant finished-product supply disruptions; imported inputs will still be needed.
- 03
Country-specific regulatory capability
Building the expertise required to assess and pursue authorisations in each intended market.
- 04
Qualified partnerships
Seeking relationships with qualified distributors and procurement organisations as readiness develops.
- 05
Progressive product diversification
Beginning with IV fluids and evaluating selected generic injectables and additional sterile medicines over time.
Strategic market roadmap
Zimbabwe
Manufacturing and launch base
Establish in Zimbabwe. Develop the manufacturing platform, seek the required authorisations and prepare for an initial domestic launch.
Selected SADC markets
Planned regional expansion
Expand across selected SADC markets. Pursue country-specific registrations and qualified distribution relationships as readiness and demand support entry.
Wider Africa
Long-term opportunity
Evaluate wider African opportunities. Assess additional markets after establishing a Zimbabwean and SADC presence, subject to local regulatory, commercial and operational conditions.
Future strategic phases, subject to readiness and regulatory approval; this roadmap does not indicate current market presence or active distribution.
Responsible Growth
Manufacturing medicines responsibly means considering patients, people and the environment.
As Biogenix develops its plans, responsible resource use, supply decisions and local skills development are intended to inform how capability is built.
Responsible Operations
- Responsible water use
- Energy efficiency
- Controlled waste handling
Responsible Supply
- Appropriate material sourcing
- Supplier qualification
- Efficient packaging choices
Skills and Communities
- Local technical capability
- Skills development
- Long-term employment potential
Partnerships
Building the future of pharmaceutical manufacturing takes committed partners.
Biogenix welcomes conversations with healthcare institutions, technology providers, qualified suppliers, development partners and organisations working to strengthen access to essential medicines.